Destiq Adverse Reactions

ADRs by SOC and CIOMS frequency category listed in order of decreasing medical seriousness within each frequency category and SOC. (See table.)

Click on icon to see table/diagram/image

Ischemic cardiac adverse events: There were uncommon reports of ischemic cardiac adverse events, including myocardial ischemia, myocardial infarction, and coronary occlusion requiring revascularization; these patients had multiple underlying cardiac risk factors. More patients experienced these events during desvenlafaxine treatment as compared to placebo (see PRECAUTIONS).
Discontinuation symptoms: Adverse drug reactions reported in association with abrupt discontinuation, dose reduction or tapering of treatment in MDD at a rate of ≥2% include: dizziness, withdrawal syndrome, nausea and headache. In general, discontinuation symptoms occurred more frequently with higher doses and with longer duration of therapy (see DOSAGE & ADMINISTRATION; PRECAUTIONS).
Adverse reactions: Pediatric patients: In general, the adverse reaction profile of Desvenlafaxine Succinate Extended Release Tablets in children and adolescents (aged 7 to 17) was similar to that seen for adults.
The most frequently reported events were: Headache, Nausea, Abdominal pain upper, Nasopharyngitis, Dizziness, Upper respiratory tract infection, Decreased appetite, Vomiting, Fatigue, and Insomnia.
When compared to adverse event rates in adults, the following events occurred more frequently in pediatric patients: Abdominal pain upper, Weight increased, Gastroenteritis viral, Dysmenorrhoea, Accidental overdose, Cough, Irritability, Oropharyngeal pain, and Sinusitis.
Geriatric use: No overall differences in safety or efficacy were observed between these patients and younger patients; however, there was a higher incidence of systolic orthostatic hypotension and increases in systolic blood pressure in patients ≥65 years of age compared to patients <65 years of age treated with desvenlafaxine.
Adverse reactions reported with other SNRIs: Although gastrointestinal bleeding is not considered an adverse reaction for desvenlafaxine succinate, it is an adverse reaction for other SNRIs and may also occur with desvenlafaxine succinate.